HighTide Therapeutics, Inc.

Equities

2511

KYG4568L1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 am EDT			5-day change	1st Jan Change
4.48 ^HKD	+0.45%		-12.33%	-65.43%

May. 21	108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024.	CI
Apr. 03	HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator	MT

HighTide Therapeutics, Inc. announced that it has received CNY 100 million in funding from Cangzhou Chuangrong Equity Investment Fund Co., Ltd.

December 16, 2023

HighTide Therapeutics, Inc. announced that it has received CNY 100 million in a pre-IPO round of funding during the week ending December 17, 2023. The transaction included participation from new investor, Cangzhou Chuangrong Equity Investment Fund Co., Ltd.

Latest news about HighTide Therapeutics, Inc.

108,000,000 Shares of HighTide Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2024.	May. 20	CI
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator	Apr. 03	MT
Hightide Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase IIb Clinical Trial Evaluating HTD1801	Apr. 03	CI
HighTide Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
HighTide Therapeutics, Inc. Announces Resignation of Mr. LI LI as A Non-Executive Director	Feb. 02	CI
HighTide Therapeutics to Set Up New Plant in China Expansion Plans	Jan. 22	MT
China's Curbs on Game Spending Pulls Down Hong Kong Stocks; One Out of Four Trading Debutants Drop at Close	Dec. 22	MT
Hightide Therapeutics Gains 7% in Hong Kong Trading Debut	Dec. 22	MT
HighTide Therapeutics, Inc. has completed an IPO in the amount of HKD 278.231 million.	Dec. 21	CI
HighTide Therapeutics, Inc. announced that it has received CNY 100 million in funding from Cangzhou Chuangrong Equity Investment Fund Co., Ltd.	Dec. 16	CI
HighTide Therapeutics, Inc. has filed an IPO in the amount of HKD 278.231 million.	Dec. 13	CI
HighTide Therapeutics, Inc. Appoints Edmund Sim as Chief Financial Officer	23-02-02	CI

Chart HighTide Therapeutics, Inc.

Duration

Period

More charts

Company Profile

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Companyâs core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.156 CNY

Average target price

15.62 CNY

Spread / Average Target

+275.86%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HIGHTIDE THERAPEUTICS, INC.	-65.43%	294M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-13.31%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.1B

Bio Therapeutic Drugs